Shoot­ing for a heav­i­ly pre-treat­ed niche can­cer mar­ket, Bi­cy­cle re­veals a 'mixed' da­ta cut

Less than two months af­ter ex­pand­ing its im­muno-on­col­o­gy part­ner­ship with Roche’s Genen­tech, Bi­cy­cle Ther­a­peu­tics tout­ed some new in-house da­ta on its lead pro­gram.

The Boston-UK biotech re­port­ed re­sults from the dose-es­ca­la­tion por­tion of a Phase I/II tri­al for BT5528, ob­serv­ing a hand­ful of re­spons­es among a dozen very sick pa­tients who pos­sess a par­tic­u­lar tu­mor ex­pres­sion. Over­all, ex­ecs viewed the da­ta as pos­i­tive, se­lect­ing a dose to use in the next por­tion of the study and hon­ing in on a po­ten­tial path for­ward in ovar­i­an and urothe­lial can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER